Everest Medicines launched its first research center for innovative medicines in Feb. 2022 in Shanghai’s Zhangjiang Hi-Tech Park. The center, covering an area of 1,730 square meters, enhances Everest Medicines’ drug discovery capabilities and develop a pipeline of potentially first-in-class or best-in-class drugs to meet unmet medical needs.

Everest develops discovery products utilizing the mRNA platform, of which it owns full intellectual property rights and full global rights. Based on its clinically-validated mRNA platform, therapeutic vaccines such as cancer vaccines will be the focus of research and discovery activities at Everest. Several of its mRNA cancer vaccines are expected to enter clinical trials in 2024 and 2025.